𝔖 Bobbio Scriptorium
✦   LIBER   ✦

A clinical trial of biochemical modulation of 5-fluorouracil with N-phosphonoacetyl-L-aspartate and thymidine in advanced gastric and anaplastic colorectal cancer

✍ Scribed by Harold E. Windschitl; Michael J. O'Connell; Harry S. Wieand; James E. Krook; Joseph Rubin; Charles G. Moertel; John W. Kugler; Delano M. Pfeifle; Richard M. Goldberg; John A. Laurie

Publisher
John Wiley and Sons
Year
1990
Tongue
English
Weight
346 KB
Volume
66
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

A phase III trial of 5-fluorouracil and
A phase III trial of 5-fluorouracil and leucovorin in the treatment of advanced colorectal cancer. A mayo clinic/north central cancer treatment group study
✍ Michael J. O'Connell πŸ“‚ Article πŸ“… 1989 πŸ› John Wiley and Sons 🌐 English βš– 498 KB πŸ‘ 2 views

The Mayo Clinic and the North Central Cancer Treatment Group (NCCTG) conducted a randomized clinical trial comparing five different combination chemotherapeutic regimens to single-agent 5-fluorouracil (5-FU), given by intravenous bolus technique (500 mg/m2 for 5 days) as a control, in the treatment

A phase II trial of weekly high dose con
A phase II trial of weekly high dose continuous infusion 5-fluorouracil plus oral leucovorin in patients with advanced colorectal cancer
✍ Enrique Aranda; AndrΓ©s Cervantes; Javier Dorta; Esperanza Blanco; Carlos FernΓ‘nd πŸ“‚ Article πŸ“… 1995 πŸ› John Wiley and Sons 🌐 English βš– 419 KB πŸ‘ 2 views

Background. In a previous Phase I1 trial, the authors showed that a weekly continuous infusion of 5-fluorouracil (5-FU) at a dose of 3.5 g/mz for 48 hours is an active treatment for advanced colorectal cancer. The overall response rate was 38.5%, and the median survival was 12 months. These data wer